UA83101C2 - 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists - Google Patents
2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonistsInfo
- Publication number
- UA83101C2 UA83101C2 UAA200607870A UAA200607870A UA83101C2 UA 83101 C2 UA83101 C2 UA 83101C2 UA A200607870 A UAA200607870 A UA A200607870A UA A200607870 A UAA200607870 A UA A200607870A UA 83101 C2 UA83101 C2 UA 83101C2
- Authority
- UA
- Ukraine
- Prior art keywords
- bisheteroaryl
- aminopyrimidines
- receptor antagonists
- adenosine receptor
- adenosine
- Prior art date
Links
- 229940121359 adenosine receptor antagonist Drugs 0.000 title 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 150000005007 4-aminopyrimidines Chemical class 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200302951A ES2234433B1 (es) | 2003-12-15 | 2003-12-15 | 4-aminopirimidinas como antagonistas de receptores de adenosina. |
| EP2004011086 | 2004-10-05 | ||
| PCT/US2004/041970 WO2005058883A1 (en) | 2003-12-15 | 2004-12-14 | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA83101C2 true UA83101C2 (en) | 2008-06-10 |
Family
ID=34702454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200607870A UA83101C2 (en) | 2003-12-15 | 2004-12-14 | 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080058356A1 (enExample) |
| JP (1) | JP2007514003A (enExample) |
| AU (1) | AU2004299461A1 (enExample) |
| BR (1) | BRPI0417478A (enExample) |
| CA (1) | CA2551944A1 (enExample) |
| EA (1) | EA010568B1 (enExample) |
| IL (1) | IL176005A0 (enExample) |
| MX (1) | MXPA06006776A (enExample) |
| NO (1) | NO20062713L (enExample) |
| SM (1) | SMP200600024B (enExample) |
| UA (1) | UA83101C2 (enExample) |
| WO (1) | WO2005058883A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0323137D0 (en) | 2003-10-03 | 2003-11-05 | Chang Lisa C W | 2,4,6- Trisubstituted pyrimidines and their different uses |
| GB0403635D0 (en) * | 2004-02-18 | 2004-03-24 | Devgen Nv | Pyridinocarboxamides with improved activity as kinase inhibitors |
| ATE502936T1 (de) * | 2005-04-11 | 2011-04-15 | Almirall Sa | 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten |
| ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| EP1976851A2 (en) * | 2006-01-17 | 2008-10-08 | Neurocrine Biosciences, Inc. | Phenoxy-substituted pyrimidines as adenosine receptor antagonists |
| AR061974A1 (es) | 2006-07-14 | 2008-08-10 | Novartis Ag | Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion |
| AU2007308154A1 (en) | 2006-10-10 | 2008-04-17 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
| US20100234341A1 (en) * | 2006-12-04 | 2010-09-16 | Marion Lanier | Substituted pyrimidines as adenosine receptor antagonists |
| WO2008070994A1 (en) | 2006-12-14 | 2008-06-19 | Nps Pharmaceuticals, Inc. | Use of d-serine derivatives for the treatment of anxiety disorders |
| JP2010522214A (ja) * | 2007-03-21 | 2010-07-01 | アルミラル， エセ．アー． | アデノシンレセプターアンタゴニストとしての置換ピリミジン |
| EP2142536B1 (en) * | 2007-04-20 | 2015-10-21 | Probiodrug AG | Aminopyrimidine derivatives as glutaminyl cyclase inhibitors |
| PT2235012E (pt) * | 2007-12-21 | 2013-08-28 | Palau Pharma Sa | Derivados de 4-aminopirimidina como antagonistas de receptor h4 de histamina |
| EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
| BRPI1011058A2 (pt) * | 2009-05-19 | 2015-08-25 | Dow Agrosciences Llc | Compostos e metodos controlar fungos |
| CA2812683C (en) | 2009-09-25 | 2017-10-10 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| WO2011106105A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| WO2011106573A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| ES2365960B1 (es) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| HUE030938T2 (en) | 2010-04-19 | 2017-06-28 | Oryzon Genomics Sa | Lysine-specific demethylase-1 inhibitors and their use |
| MX341732B (es) | 2010-07-29 | 2016-08-30 | Oryzon Genomics S A * | Inhibidores de la demetilasa lsd1 basados en arilciclopropilamina y sus usos médicos. |
| WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| CA2807661C (en) | 2010-08-11 | 2019-09-10 | Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| EP3981395A1 (en) | 2011-02-08 | 2022-04-13 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| EP2741741A2 (en) * | 2011-05-19 | 2014-06-18 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| WO2013052526A1 (en) * | 2011-10-06 | 2013-04-11 | Merck Sharp & Dohme Corp. | Triazolyl pde10 inhibitors |
| WO2013057322A1 (en) | 2011-10-20 | 2013-04-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| BR112014009306B1 (pt) | 2011-10-20 | 2021-07-20 | Oryzon Genomics S.A. | Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1 |
| EP3062791B1 (en) | 2013-10-28 | 2020-01-08 | Drexel University | Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder |
| BR112017023821A2 (pt) | 2015-05-06 | 2018-07-31 | Leidos Biomedical Res Inc | moduladores de k-ras |
| SG10202111808WA (en) | 2015-08-11 | 2021-11-29 | Novartis Ag | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer |
| NZ754731A (en) * | 2017-01-20 | 2023-02-24 | Arcus Biosciences Inc | Azolopyrimidine for the treatment of cancer-related disorders |
| BR112019021899A2 (pt) * | 2017-04-20 | 2020-08-18 | The Regents Of The University Of California | moduladores de k-ras |
| JP7295034B2 (ja) * | 2017-05-05 | 2023-06-20 | アーカス バイオサイエンシズ インコーポレイティド | 癌関連障害の治療のためのキナゾリン－ピリジン誘導体 |
| JOP20190279A1 (ar) | 2017-05-31 | 2019-11-28 | Novartis Ag | الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة |
| US11478479B2 (en) | 2018-02-16 | 2022-10-25 | Arcus Biosciences, Inc. | Dosing with an azolopyrimidine compound |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4725600A (en) * | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
| DE3905364A1 (de) * | 1989-02-22 | 1990-08-23 | Hoechst Ag | Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool |
| DE19710435A1 (de) * | 1997-03-13 | 1998-09-17 | Hoechst Ag | Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen |
| JPH11158073A (ja) * | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンａ３拮抗剤 |
| DE19836697A1 (de) * | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| US6518424B1 (en) * | 1998-11-12 | 2003-02-11 | Elan Pharmaceuticals, Inc. | Substituted pyrimidine compositions and methods of use |
| BR0108611A (pt) | 2000-02-25 | 2003-05-06 | Hoffmann La Roche | Moduladores de receptor de adenosina |
| ATE284712T1 (de) * | 2000-04-26 | 2005-01-15 | Eisai Co Ltd | Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide |
| JP4272338B2 (ja) * | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| US6716851B2 (en) * | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| AU2002228922A1 (en) * | 2000-12-12 | 2002-06-24 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| WO2002060392A2 (en) * | 2001-01-31 | 2002-08-08 | Synaptic Pharmaceutical Corporation | Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| US7024532B2 (en) | 2001-08-09 | 2006-04-04 | Matsushita Electric Industrial Co., Ltd. | File management method, and memory card and terminal apparatus that make use of the method |
| TWI330183B (enExample) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| AU2004289518A1 (en) * | 2003-11-10 | 2005-05-26 | Merck Sharp & Dohme Limited | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
-
2004
- 2004-12-14 BR BRPI0417478-0A patent/BRPI0417478A/pt not_active Application Discontinuation
- 2004-12-14 US US10/582,704 patent/US20080058356A1/en not_active Abandoned
- 2004-12-14 WO PCT/US2004/041970 patent/WO2005058883A1/en not_active Ceased
- 2004-12-14 AU AU2004299461A patent/AU2004299461A1/en not_active Abandoned
- 2004-12-14 EA EA200601160A patent/EA010568B1/ru not_active IP Right Cessation
- 2004-12-14 UA UAA200607870A patent/UA83101C2/ru unknown
- 2004-12-14 SM SM200600024T patent/SMP200600024B/it unknown
- 2004-12-14 MX MXPA06006776A patent/MXPA06006776A/es active IP Right Grant
- 2004-12-14 CA CA002551944A patent/CA2551944A1/en not_active Abandoned
- 2004-12-14 JP JP2006545817A patent/JP2007514003A/ja active Pending
-
2006
- 2006-05-30 IL IL176005A patent/IL176005A0/en unknown
- 2006-06-12 NO NO20062713A patent/NO20062713L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005058883A1 (en) | 2005-06-30 |
| MXPA06006776A (es) | 2007-03-23 |
| CA2551944A1 (en) | 2005-06-30 |
| SMAP200600024A (it) | 2006-07-19 |
| JP2007514003A (ja) | 2007-05-31 |
| IL176005A0 (en) | 2006-10-05 |
| SMP200600024B (it) | 2006-07-19 |
| US20080058356A1 (en) | 2008-03-06 |
| EA010568B1 (ru) | 2008-10-30 |
| NO20062713L (no) | 2006-08-01 |
| BRPI0417478A (pt) | 2007-05-08 |
| EA200601160A1 (ru) | 2006-12-29 |
| AU2004299461A1 (en) | 2005-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA83101C2 (en) | 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists | |
| NZ522326A (en) | Adenosine A2A receptor antagonists | |
| MXPA04000886A (es) | Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos. | |
| GEP20084391B (en) | Pyrazoles and methods of making and using the same | |
| MXPA05011643A (es) | 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension. | |
| UA92637C2 (en) | Pyridine[3,4-b]pyrazinones | |
| MY141196A (en) | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | |
| WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
| WO2001066534A3 (en) | Cyclic and bicyclic diamino histamine-3 receptor antagonists | |
| SE0300010D0 (sv) | Novel Compounds | |
| NO20054208L (no) | Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter | |
| SE0201544D0 (sv) | Novel compounds and thier use | |
| TW200505823A (en) | CaSR antagonist | |
| DE602004018637D1 (de) | A2a-adenosinrezeptorantagonisten | |
| MY140630A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| MX2008001606A (es) | Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico. | |
| TW200504029A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| GEP20094697B (en) | Condensed purine derivatives as a1 adenosine receptor antagonists | |
| GEP20105095B (en) | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | |
| CA2527093A1 (en) | 3-fluoro-piperidines as nmda/nr2b antagonists | |
| UA83832C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и их применение | |
| IS2424B (is) | Þíenó[2,3-d]pýrimidín með sameinaðri LH og FSH gerandefnisvirkni | |
| MXPA04001419A (es) | Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson. | |
| SI1673354T1 (sl) | Arilindenopiridini in arilindenopirimidini in njihova uporaba kot antagonisti adenozinskih A2a-receptorjev | |
| DE502004011919D1 (de) | -trien-3-yl sulfamate |